Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Performance

SENS opened at $0.41 on Wednesday. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The business has a fifty day simple moving average of $0.33 and a 200 day simple moving average of $0.37. Senseonics has a 1 year low of $0.25 and a 1 year high of $0.75. The company has a market capitalization of $241.70 million, a PE ratio of -3.12 and a beta of 0.77.

Insider Transactions at Senseonics

In other news, CEO Timothy T. Goodnow acquired 315,000 shares of Senseonics stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the purchase, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Frederick T. Sullivan bought 124,933 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $0.38 per share, with a total value of $47,474.54. Following the completion of the transaction, the chief financial officer now directly owns 2,478,844 shares in the company, valued at approximately $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC lifted its stake in Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares during the last quarter. Symmetry Partners LLC bought a new position in shares of Senseonics in the 3rd quarter valued at $164,000. GSA Capital Partners LLP bought a new position in shares of Senseonics in the 3rd quarter valued at $117,000. FMR LLC boosted its holdings in shares of Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after acquiring an additional 167,970 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after acquiring an additional 179,103 shares during the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.